The Baltimore Convention Center (BCC) is now operating an outpatient infusion center to administer monoclonal antibody therapy as a treatment for COVID-19.

The Federal Drug Administration (FDA) has authorized these treatments for COVID-19 on an emergency basis.

Self-Referrals for COVID Infusion Therapy

Typically patients are referred by a healthcare provider, such as their primary care doctor. But if you do not have a primary care provider, you may click the button to self-refer.

BCC Infusion Center Self-Referral Form

The Baltimore Convention Center Infusion Center team will review the referral information and contact the patient as soon as possible, between 8:30 am and 6 pm, Monday through Friday. If monoclonal treatment is indicated, we will coordinate services right away.

About Monoclonal Antibody Therapy

Administered by IV (through a vein), these outpatient COVID treatments have been shown to reduce hospitalization or emergency room visits when received within 10 days after the start of COVID symptoms.

The monoclonal antibody therapy being offered at the BCC COVID Infusion Center is a combination of casirivimab and imdevimab (more widely known as Regeneron, the manufacturer's name) – Patient Fact Sheet (also available in Spanish).

Who Can Receive Monoclonal Antibody Therapy

These medicines are authorized for use for people age 12 and older, who have COVID-19 but are not hospitalized and who meet other specific criteria. Both treatments have the same criteria, which include, but are not limited to:

  • Mild to moderate symptoms
  • High risk for developing severe symptoms or the need for hospitalization

For more information about these treatments, the specific criteria and potential side effects, please read the Patient Fact Sheet, linked above.